angiotensin II receptor antagonist

(redirected from Angiotensin-receptor blocker)
Also found in: Encyclopedia.

angiotensin II receptor antagonist

Any of a family of agents (e.g., losartan and valsartan) that block the binding of angiotensin II (A-II) to their cognate cell receptors—AT1, AT2 and others. First-generation ARAs included the sartan family of agents, which only block AT1, interacting with the amino acids in the transmembrane domains to block the binding of A-II to AT1.

ARAs are an alternative to ACEI therapy in patients with CHF; unlike ACEIs, ARAs do not interfere with bradykinin and prostaglandin metabolism, interference of which has been linked to some of the adverse effects of ACEI therapy, particularly to cough and angioedema.

angiotensin II receptor antagonist

Pharmacology Any of a family of agents-eg losartan and valsartan, which block the binding of angiotensin II–A-II to its cognate cell membrane receptors–AT1, AT2, and others; 1st generation ARAs included the sartan family of agents, which only block AT1, interacting with the amino acids in the transmembrane domains, blocking the binding of A-II to AT1; an alternative to ACEI therapy for Pts with CHF; unlike ACEIs, ARAs do not interfere with bradykinin and prostaglandin metabolism, interference which has been linked to some of the adverse effects of ACEI therapy, particularly to cough and angioedema.
References in periodicals archive ?
Lambert and her associates designed this pilot study because of previously reported results from other groups showing favorable effects of losartan on animal models of emphysema or other lung disease, as well as suggestions from nonprospective clinical studies of benefits from angiotensin-receptor blockers on lung function and on chronic obstructive pulmonary disease (COPD) in particular.
Angiotensin-receptor blockers and cancer: urgent regulatory review needed.
Start patients on a half tablet daily of the lowest dose available for a fixed-dose combination of a diuretic plus either an angiotensin-converting enzyme inhibitor or angiotensin-receptor blocker.
It remains a clinical question [as to] who should get a [beta]-blocker first and who should first get an ACE inhibitor or angiotensin-receptor blocker," Dr.
In contrast, a drug combination that includes an ACE inhibitor or an angiotensin-receptor blocker is fine for initial treatment of African Americans with advanced renal disease, as shown by the African American Study of Kidney Disease and Hypertension, Dr.
None of the patients was taking an ACE inhibitor or angiotensin-receptor blocker (ARB) at baseline.
All patients were treated with optimal medical therapy: 90% were treated with an angiotensin-converting enzyme inhibitor or an angiotensin-receptor blocker, 65% with a [beta]-blocker, and 55% with spironolactone.
22--the first-line antihypertensive drug should be an agent that blocks the renin-angiotensin system: either an ACE inhibitor or an angiotensin-receptor blocker.
Moreover, the angiotensin-receptor blocker also induces greater regression of left ventricular hypertrophy (LVH) and is better tolerated, said Dr.
The dose of an angiorensin-converting enzyme (ACE) inhibitor or angiotensin-receptor blocker (ARB) should be pushed to minimize proteinuria, Dr.
This report also discusses the perceived use of diabetic medications in the DN patient population, among other agents used such as angiotensin-converting enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs).
Investigators in the United States, taking note from the Heart Failure Assessment of Reduction in mortality and Morbidity (CHARM) study, have conducted several controlled trials of angiotensin-receptor blockers (ARBs) to see their effect on cancer rates.

Full browser ?